Abstract
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease of increasing public health importance around the world. COPD is charactarized by chronic airflow limitation and a range of pathological changes in the lung. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
Although the most critical factor of acquiring COPD is smoking [1] , only 15 to 20% of chronic smokers get this disease [2, 3] . This indicates the presence of additional genetic or environmental factors which contribute to the development of COPD. Environmental factors that have been associated with COPD include viral infections, especially during childhood, air pollution and most commonly smoking. The genetic risk factor that is best documented is a severe hereditery deficiency of alfa-1 antitrypsin [4] .
A hereditary basis for COPD was first suggested in 1845 [5] , but this observation remained essentially uninvestigated until the mid-twentieth century. At that time, several investigators have shown increased prevalence of COPD in relatives of cases, compared to relatives the prevalence of COPD in controls [6] [7] [8] . Studies on twins also suggest a genetic basis in the development of COPD [9] [10] [11] .
Among the candidate genes that have been studied in COPD are genes that effect the production of proteases and antiproteases, genes that modulate the metabolism of toxic substances in cigarette smoke, genes involved in mucociliary clearance and airway hyperactivity and genes that influence inflammatory mediators [12] [13] .
Genes that are involved in inflammatory processes include Tumor Necrosis Factor-, immunoglobulins, and Vitamin D Binding Protein (VDBP) [12] [13] .
VDBP is a 55kDa protein secreted by the liver which is able to bind Vitamin D 1, extracellular actin and endotoxin. VDBP is also known to undergo conversion to a potent macrophageactivating factor [14] . Thus, VDBP could exert an important effect on the intensity of the inflammatory reaction. The gene for VDBP is located on chromosome 4q11-q13 [15] and two common substitutions in exon 11 result in three possible isoforms, termed 1F, 1S and 2 [16] .
Recent data indicate that the allele frequencies vary considerably among populations. [18] .
There are some studies in the literature investigating the association of VDBP polymorphisms with the development of COPD; however, contradictory results have been reported for COPD patients of different ethnicities or even within the same ethnic group [8, [17] [18] [19] [20] [21] . Individuals who have one or two copies of allele 2 have been shown to be protected against to COPD [17, 19, 20] , whereas the 1F-1F genotype has been associated with increased risk [17] [18] [19] [20] [21] .
In this study, we investigated the allele frequencies in the Turkish population and the association of VDBP gene polymorphism with the development of COPD in Turkish patients according to the smoking status.
Materials And Methods
Blood samples were collected from 75 patients (66 males and 9 females) with COPD (all smokers COPD group), 36 healthy smokers (C group) and 19 never-smokers (H group).
The confirmative diagnosis of COPD was based on the subject's medical history, physical examination and pulmonary function tests, using GOLD guidelines [22] . Pulmonary function tests were performed to determine FVC, FEV 1 , FEV 1 /FVC, TLC and DLCO. Patients with FEV 1 values ≥ 80% were excluded from this study. All patients had moderate-to-severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease classification of severity [22] .
Criteria for involving the study were as followed; smoking more than 10 packages of cigarette per year, postbronchiodilator values for FEV 1 Non-smoker group consists of the voluntary people who work in our hospital, with a FEV 1 /FVC >70% ratio who do not have any lung disease such as COPD or asthma or any systemic disease and who are not exposed to passive smoking.
Genomic DNA for molecular analysis was isolated from peripheral blood samples by 
Results
A total of 130 subjects, including 75 COPD patients, 36 healthy smokers and 19 nonmokers as control subjects were studied. The mean age of the COPD patients was 64,4±11,0, malefemale ratio was 66/9, number of packages smoked per year was 51,431,1 and the In healthy smoker and non-smoker control groups the mean age was 50,535,2 and 35,29,5, respectively. Male/female ratio was 18/18 and 10/9, respectively. Number of packages smoked per year was 36,929,2 in healthy smoker controls.
The distribution of the six major genotypes in the patients and the control groups are as follows: 1S-1S genotype in patient group was 22.7%, whereas 22.3% in healthy smoker controls and 47.4% in healthy non-smoker controls. The results for 1F-1S was 22.7%, 33.3% and 15.8%, respectively. For 1F-1F; the results were 5.3%, 11.1% and 5.2%, respectively. 32%, 19.4% and 31.6%, respectively were the distribution ratios for 1S-2 group. In 1F-2 group, we found 13.3% and 5.6% while there was no result for healthy non-smoker group.
Similar to this situation, in 2-2 group there was no result for for healthy non-smoker group whereas 4% for patient group and 8.3% for healthy smoker group were the ratios. First, we compared the patient vs. healthy smoker controls to find the statistical differences where p0.05 was meant to be statistically significant. In the latter analysis, we compared the patient group vs. healthy non-smoker controls group to see the differences in two groups. The frequencies are not significantly different between the patient and control groups except one group, which is the 1S-1S genotype with a significant difference between the patient and the healthy non smoking group with a p value of 0.032. This may suggest that, having 1S-1S The frequencies of the three alleles in COPD patients were also compared with the frequencies in the healthy smoking and non-smoking control groups. In the COPD patients, the frequencies of the 1S, 1F and 2 alleles were 0.5, 0.23 and 0.27, respectively. In the healthy smoker and nonsmoker groups the frequencies were 0.49, 0.30 and 0.21 and 0.71, 0.13 and 0.16, respectively. The results are presented in Table 3 . Our study revealed a significant difference in the prevalence of the allele 1S and 1S-1S genotype in the patients and nonsmoker groups. We did not find any significant differences among the patients and the control groups who had 1F or 2 alleles and correlating genotypes Table 4 , we did not find any association between the COPD stages and VDBP genotype or allele frequencies. The differences of the genotype frequency between these three groups were not statistically significant. 
Discussion
Variability in the susceptibility to develop COPD is related to both genetic and environmental factors. Cigarette smoking is the major risk factor for COPD [1, 23] . However, it is estimated that only 15-20% of chronic heavy smokers develop symptomatic COPD [2, 3, 24, 25] .
Numerous epidemiological studies also provide compelling evidence that genetic factors influence the development of COPD [26] . Current theories suggest that inflammation and oxidative stress induced by smoking may lead to a proteolytic imbalance and progressive lung structural derangement. Therefore disease susceptibility is controlled by inherited variations in genes involved in antiproteolysis, metabolism of toxic substances in the cigarette smoke and the efficiency of mucociliary clearance in the lung. A variety of studies have examined candidate gene loci with association studies, comparing the distribution of variants in genes hypothesized to be involved in the development of COPD in patients and control subjects [27] .
One important candidate gene that is involved in the inflammatory process is VDBP.
Numerous isoforms of VDBP have been identified by isoelectric focusing. Two common [16] . It has been reported that individuals homozygous for allele 2 are significantly underrepresented among COPD patients, illustrating a protective role for allele 2 in COPD [17] . It has also been shown that the genotypes which contain allele 2 (1F-2, 1S-2 and 2-2)
had a protective effect [19, 20] . However, this observation has not been confirmed by a subsequent study [18] . In accordance with this study, we did not find an association between the genotype containing allele 2 and susceptibility to COPD. In our study the frequency of allele 2 in the control group is slightly lower than reported by Schellenberg et al. [17] and Ishii et al. [18] for the Caucasian and Japanase population, respectively. The incidence of allele 2 carrying genotypes and allele 2 frequencies were similar in both COPD patients and the control groups. In addition, Horne et al. [19] have shown a significantly increased risk for COPD in 1F homozygous individuals and Ishii et al. [18] confirmed this result in the Japanese population. Our finding is discordant with these results since we did not observe a difference in the frequency of VDBP genotypes between the patients and controls except 1S-1S genotype.
As a result, we have not found any evidence that differences in the VDBP gene 1F and 2 alleles could confer a genetic predisposition to COPD except the allele 1S. 1S allele and 1S-1S genotype were significantly more frequent in non-smoker controls. These results indicate that 1 S allele in homozygous state may be protective against to COPD in smoking people.
Therefore, 1S allele may have a role in detoxification of substances which is found in smoke.
This may be related to the posttranslational modification of VDBP. It has been shown that macrophage activating factor is formed from VDBP by modification of an oligosaccharide side chain [14] . It has also been reported that isoforms of VDBP have different deglycosylation pathways [14] . Therefore, in addition to the possibility that VDBP gene polymorphism modulates neutrophil and monocyte chemotaxis, the difference in glycosylated forms of 1F, 1S and 2 isoforms may also effect activation of macrophages. Recently, Hautamaki et al [27] reported that its metalloproteinase plays a key role in the pathogenesis of emphysema. This report supports the hypothesis that the glycosylation of VDBP may have a role in susceptibity to COPD.
In conclusion, our results do not support previous studies which indicate a protective or susceptibility effect of VDBP 2 and 1F alleles in development of COPD, respectively; as we found a complete new result which is, having 1S-1S genotype may have protective effect on 
